Divi's Laboratories Limited
DIVISLABStructural risk assessment following Q4-FY26 | 31 Mar 26 earnings.
Q3-FY26 | 31 Dec 25
10
Risk Score
Q4-FY26 | 31 Mar 26
15
Risk Score
🔴Risk increased by +5 points
Flagium detected:
- ⚠Inventory Stress
- ⚠Working Capital Expansion
- ⚠Industrial Margin Stress
ℹ️ Executive Summary
Divi's Laboratories Limited posted steady top-line growth and bottom-line stability, demonstrating resilient execution in its core markets. While the underlying business remains fundamentally sound, the presence of 3 active risk warnings highlights minor operational or working capital inefficiencies to keep on the watch list.
🛡️ Sentinel Insight
"Divi's Laboratories Limited currently sits within Flagium's Stable category. However, recent periods have introduced early signs of competitive and operating pressure. Despite positive top and bottom-line growth, triggers like 'Inventory Stress', 'Working Capital Expansion' indicate underlying structural risk. Current deterioration appears cyclical rather than existential."
The Quarter at a Glance
| Metric | Q4-FY26 | 31 Mar 26 | Q4-FY25 | 31 Mar 25 | Change |
|---|---|---|---|
| Revenue | ₹2,986.0 Cr | ₹2,671.0 Cr | +11.8% |
| EBIT Margin | 32.25% | 32.35% | -10 bps |
| Net Profit (PAT) | ₹751.0 Cr | ₹662.0 Cr | +13.4% |
| Interest Expense | ₹6.0 Cr | ₹1.0 Cr | +500.0% |
← scroll to see all →
What Changed Beneath the Headlines?
Revenue Growth
Quarterly revenue changed by +11.8% YoY, reflecting demand and volume updates.
Net Profit Expansion
Profit after tax changed by +13.4% YoY, settling at ₹751.0 Cr.
Operating Margins
Operating margin declined by 10 bps YoY to 32.25%.
Flagium Risk Signals
Inventory growth (22.2%) significantly outpaced revenue growth (11.8%).
Working capital expansion detected: Receivable days increased by -2.3%.
DIVISLAB: Raw material costs consumed an additional 5.8% of revenue YoY.
What the financials are implicitly signaling
Flagium's structural analysis indicates:
- •Margin defense remains a priority as raw material costs or operating expense pressures rise.
- •Capacity utilization calibration is being monitored to align with slow volume intake.
- •Working capital conversion cycles require active support to sustain cash conversions.
Signals to Monitor Next Quarter
Resolution of 'Industrial Margin Stress' warning: DIVISLAB: Raw material costs consumed an additional 5.8% of revenue YoY.
Raw material price movement and its impact on operating margins.
Working capital efficiency and cash flow conversions.
Domestic demand recovery and segment-wise volume growth.
Historical Quality Trend
Last 6 Quarters| Quarter | Risk Score | Trend | Current Risk Class |
|---|---|---|---|
| Q4 FY26 | 15 | ↑ | 🟢 Stable |
| Q3 FY26 | 10 | ↑ | 🟢 Stable |
| Q2 FY26 | 5 | ↓ | 🟢 Stable |
| Q1 FY26 | 10 | ↑ | 🟢 Stable |
| Q4 FY25 | 5 | ↑ | 🟢 Stable |
| Q3 FY25 | 0 | → | 🟢 Stable |
← scroll to see all →
What to do next
Explore DIVISLAB's full structural risk profile — 12Q score trajectory, pillar breakdown, flag history, and peer benchmarking.
View DIVISLAB profile →See how Pharmaceuticals peers and the broader market are positioned. Identify sector-wide stress or rotation signals.
Open market monitor →Check how this Q4-FY26 | 31 Mar 26 result affects your portfolio's overall risk exposure and concentration.
Review your portfolio →Disclaimer
Flagium AI is an automated financial data analytics platform. Analysis reports are compiled programmatically from public regulatory XBRL submissions (NSE/BSE). This evaluation does not constitute investment advice, financial planning, or recommendations to buy, sell, or hold any security. Please consult a SEBI-registered investment advisor before acting on any data presented.